We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




SLAS Hosts First Annual China Conference and Exhibition

By LabMedica International staff writers
Posted on 27 Dec 2010
The newly merged Society for Laboratory Automation and Screening (SLAS; St. More...
Charles, IL, USA) hosted its First Annual China Conference and Exhibition in Shanghai (China), at the Shangri-La Hotel, on December 7-9, 2010. The newly launched event set the framework for future SLAS endeavors in Asia Pacific.

The meeting combined a series of presentations on new technologies and experimental approaches for hit and lead identification with the opportunity for local scientists to network with in an informal and engaging environment.

The conference hosted 25 exclusive scientific lectures presented by eminent scientists. Christopher Lipinski, PhD, from Melior Discovery (Exton, PA, USA) discussed the issue of compound failure in preclinical and clinical development and strategies to reduce this failure rate through improvements to the physiochemical properties of drug candidates.

Wei Zhang PhD, National Institutes of Health Chemical Genomics Center (NIH; Bethesda, MD, USA) presented on the use of cellular phenotypic screens for lead identification to enable the identification of molecules with improved efficacy.

At the exhibition, TTP Labtech (Royston, United Kingdom) launched the Mirrorball, a new laser scanning microplate cytometer designed primarily for the study of antibody/antigen interactions. The new instrument offers increased sensitivity and multiplexing capability compared to existing instruments.

As a complimentary benefit to conference participants, SLAS partnered with the Shanghai Zhangjiang Technology Park (Shanghai, China) for a private pre-event function highlighted by three additional scientific lectures. The primary presentation was given by Xin Xie, PhD, head of assay development, Chinese National Center for Drug Screening (Shanghai, China).

A guided tour of the technology park was given to meeting participants. The park houses 110 research and development institutions and 327 companies including leading pharmaceutical companies.

According to SLAS scientific program committee chair Steven Rees at GlaxoSmithKline (Stevenage, United Kingdom), the conference was "phenomenally successful.” He added, "Bringing SLAS to Shanghai has demonstrated the interest and expertise in drug discovery in China, and the enthusiasm of the local scientists to partner with the SLAS community.”

Related Links:

Society for Laboratory Automation and Screening
GlaxoSmithKline
Melior Discovery
TTP Labtech


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.